FINANCIAL TRUST COMPANY INC For the Period ♦11112 to 413W12 Note P indicates position adjusted for Pending Trade Activity. Unrealized GainiLoss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional information. Equity Detail Price Quality Value Adjusted Tax Cost Unrealized Gain/Loss Est. Annual Inc Yield Original Cost Accrued Div. US Large Cap Equity ARIAD PHARMACEUTICALS INC 16.30 16,535.000 269,520.50 251,475.52 18,044.96 04033A-10-0 ARIA BIDDEN IDEC INC 134.01 2.095 000 280 750 95 250,454.95 30,296.00 09062X-10-3 BIIB DB CONT BUFF EQ MS 08/07/12 81.37 1000000,000 813,700.00 1,000,000.00 (186,300.00) 25% CONTIN BARRIER- 13%CPN 30% CAP INITIAL LEVEL-07)1511 MS.21.09 2515A1-A7-6 HSBC MARKET PLUS SPX 06/17113 101.67 5,000,000.000 5,083,500.00 5,000,000.00 83,500.00 72% KO BARRIER- 0%CPN ,UNCAPPED INITIAL LEVEL-0211 N12 SPX:1350.50 4042K1-XQ-1 SO MARKET PLUS SPX 02107/13 108.93 2,000,000.000 2.178,600 00 2,000,000 00 178,600.00 75% CONTIN BARRIER- 6.25%CPN ,UNCAPPED INITIAL LEVEL-08/03/11 SPX:1.260.34 78423A-2Y-7 Total US Large Cap Equity $8.626.071.45 $8.501.930.47 3124.140.98 S0.00 0.00% JP Morgan Acco LI ne Page 5 of 26 Consolidated Statement Page 8 Confidential Treatment Requested by JPMorgan Chase CONFIDENTIAL JPM-SDNY-000 15830 SDNY_GM_00285028 EFTA01493007